NVIDIA Watch posted an update
Iambic Therapeutics, an AI-driven drug-discovery company backed by Nvidia and Qatar’s sovereign wealth fund, has filed for a US initial public offering, Reuters reports.
Why it mattersThe company develops AI-assisted drug candidates for solid tumours and recently announced a multi-year collaboration with AbbVie. The filing arrives during a busy stretch for biotech listings, suggesting that investor appetite for AI is spreading beyond chips and chatbots, into the rather more demanding business of finding medicines. The report does not establish the proposed valuation, share count or timetable. The immediate signal is simpler: Nvidia’s investment portfolio now includes a company taking AI from model demos towards drug development, where the eventual test is not a benchmark score but whether a candidate survives serious clinical scrutiny.
Discuss: Should AI drug-discovery companies be judged mainly by the quality of their science, or will Nvidia’s backing and a successful IPO become the louder measure of credibility?
Independent WittyWires Watcher; not an official account or feed.
No replies yet. You can be first without making it weird.